ROS1 and non-small cell lung carcinoma: Interestingly, MET exon14-mutated NSCLC patients showed very low TMB levels, similarly to BRAF and ROS1 mutant NSCLC, which represent other sub-groups of patients with an absence of clinical benefits from immunotherapy [79].